Research advances in oxidative stress and mitochondrial permeability transition in liver failure

Wang KeFei; Zhu YueKe; Meng QingHua

doi:10.3969/j.issn.1001-5256.2013.09.021

Issue 9

Sep. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(9): 711-714

PDF( 688 KB)

Research advances in oxidative stress and mitochondrial permeability transition in liver failure

DOI: 10.3969/j.issn.1001-5256.2013.09.021

Beijing Youan Hospital, Capital Medical University

Research funding:

Received Date: 2013-03-21
Published Date: 2013-09-20

Abstract

Abstract

Major treatment options for liver failure include clinical medical treatment, and prevention of complications) , artificial liver, liver transplantation, and stem cell transplantation. While these means are known to have produced favorable outcomes, some patients died due to acute and severe onset of disease or treatment delays. Oxidative stress has emerged as a research hotspot in recent years and antioxidant treatment has been drawing increasing attention. Outlines research developments in recent years and reviews the association of oxidative stress injury and mitochondrial permeability transition pore ( MPTP) with liver failure, in an effort to shed light on the importance of oxidative stress in the pathogenesis of liver failure and offer a theoretical basis and ideas for antioxidant therapy in the future.
- liver failure,
- mitochondrial membranes,
- oxidative stress

FullText(HTML)

References(48)

References

[1]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure[J].Chin J Hepatol, 2006, 14 (9) :643-646. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14 (9) :643-646.

[2]KUMAR A, DAS K, SHARMA P, et al.Hemodynamic studies in acute-on-chronic liver failure[J].Dig Dis Sci, 2009, 54 (4) :869-878.

[3]KHAN SA, SHAH N, WILLIAMS R, et al.Acute liver failure:a review[J].Clin Liver Dis, 2006, 10 (2) :239-258.

[4]TURRENS JF.Superoxide production by the mitochondrial respiratory chain[J].Biosci Rep, 1997, 17 (1) :3-8.

[5]WANG QL, WANG HY, WANG SR.Assessment of the state of oxidative stress[J].Chin J Pathophysiol, 2005, 21 (10) :2068-2074. (in Chinese) 王秋林, 王浩毅, 王树人, 等.氧化应激状态的评价[J].中国病理生理杂志, 2005, 21 (10) :2068-2074.

[6]WITKO-SARSAT V, FRIEDLANDER M, CAPEIKKEREBLANDIN C, et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia[J].Kidney Into, 1996, 49 (5) :1304-1313.

[7]LIU H, HAN T, TIAN J, et al.Monitoring oxidative stress in acute-on-chronic liver failure by advanced oxidation protein products[J].Hepatol Res, 2012, 42 (2) :171-180.

[8]CHEN Y, YANG Y, MILLER ML, et al.Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure[J].Hepatology, 2007, 45 (5) :1118-1128.

[9]LIU J, TAN H, SUN Y, et al.The preventive effects of heparinsuperoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice[J].Mol Cell Biochem, 2009, 327 (1-2) :219-228.

[10]BOSOI CR, ROSE CF.Oxidative stress:a systemic factor implicated in the pathogenesis of hepatic encephalopathy[J].Metab Brain Dis, 2013, 28 (2) :175-178.

[11]BOVERIS A, CHANCE B.The mitochondrial generation of hydrogen peroxide.General properties and effect of hyperbaric oxygen[J].Biochem J, 1973, 134 (3) :707-716.

[12]ST-PIERRE J, BUCKINGHAM JA, Roebuck SJ, et al.Topology of superoxide production from different sites in the mitochondrial electron transport chain[J].J Biol Chem, 2002, 277 (47) :44784-44790.

[13]STANIEK K, NOHL H.Are mitochondria a permanent source of reactive oxygen species?[J].Biochim Biophys Acta, 2000, 1460 (2-3) :268-275.

[14]LI F, SONVEAUX P, RABBANI ZN, et al.Regulation of HIF-1alpha stability through S-nitrosylation[J].Mol Cell, 2007, 26 (1) :63-74.

[15]NOHL H, GILLE L, STANIEK K.The mystery of reactive oxygen species derived from cell respiration[J].Acta Biochim Pol, 2004, 51 (1) :223-229.

[16]BEDARD K, KRAUSE KH.The NOX family of ROS-generating NADPH oxidases:physiology and path physiology[J].Physiol Rev, 2007, 87 (1) :245-313.

[17]CHANDEL NS, MCCLINTOCK DS, Feliciano CE, et al.Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia:a mechanism of O2sensing[J].J Biol Chem, 2000, 275 (33) :25130-25138.

[18]ALLEN RG, BALIN AK.Oxidative influence on development and differentiation:An overview of a free radical theory of development[J].Free Radic Biol Med, 1989, 6 (6) :631-661.

[19]ANDREYEV AY, KUSHNAREVA YE, STARKOV AA.Mitochondrial metabolism of reactive oxygen species[J].Biochemistry (Mosc) , 2005, 70 (2) :200-214.

[20]RHEE SG.Cell signaling.H2O2, a necessary evil for cell signaling[J].Science, 2006, 312 (5782) :1882-1883.

[21]KINNALLY KW, PEIXOTO PM, RYU SY, et al.Is MPTP the gatekeeper for necrosis, apoptosis, or both?[J].Biochim Biophys Acta, 2011, 1813 (4) :616-622.

[22]HAUSENLOY DJ, ONG SB, YELLON DM.The mitochondrial permeability transition pores as a target for preconditioning and post conditioning[J].Basic Res Cardiol, 2009, 104 (2) :189-202.

[23]SIEMEN D, ZIEMER M.What is the nature of the mitochondrial permeability transition pore and what is it not?[J].IUBMB Life, 2013, 65 (3) :255-262.

[24]HAWORTH RA, HUNTER DR.The Ca2+-induced membrane transition in mitochondria II.Nature of the Ca2+trigger site[J].Arch Biochem Biophys, 1979, 195 (2) :460-467.

[25]BONORA M, BONONI A, De MARCHI E, et al.Role of the c subunit of the FO ATP syntheses in mitochondrial permeability transition[J].Cell Cycle, 2013, 12 (4) :674-683.

[26]REUTENAUER J, DORCHIES OM, PATTHEY-VUADENS O, et al.Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for duchene muscular dystrophy[J].Br J Pharmacol, 2008, 155 (4) :574-584.

[27]RAMACHANDRAN A, LEBOFSKY M, BAINES CP, et al.Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury[J].Free Radic Res, 2011, 45 (2) :156-164.

[28]SUSIN SA, DAUGAS E, RAVAGNAN L, et al.Two distinct pathways leading to nuclear apoptosis[J].J Exp Med, 2000, 192 (4) :571-580.

[29] PEIXOTO PM, RYU SY, DEJEAN LM.et al.Is MPTP the gatekeeper for necrosis, apoptosis, or both?[J].Biochim Biophys Acta, 2011, 813 (4) :616-622.

[30]KANG KA, KIM JS, ZHANG R, et al.Induction of hemeoxygenase-1 by plant extract KIOM-79 via Akt pathway and NF-E2 related factor 2 in pancreatic beta-cells[J].J Toxicol Environ Health A, 2008, 71 (20) :1392-1399.

[31]GALLUZZI L, MORSELLI E, KEPP O, et al.Mitochondrial gate ways to cancer[J].Mol Aspects Med, 2010, 31 (1) :1-20.

[32]LIAO MY, ZHOU KJ, et al.Changes of mitochondrial permeability transition during rat liver regeneration[J].Acad J Second Military Med Univ, 2004, 25 (3) :292-294. (in Chinese) 缪明永, 朱克军, 汪振诚, 等.大鼠肝再生时线粒体通透性转换的变化[J].第二军医大学学报, 2004, 25 (3) :292-294.

[33]BERNARDI P.Modulation of the mitochondrial cyclosporin Asensitive permeability transition pores by the proton electrochemical gradient.Evidence that the pore can be opened by membrane depolarization[J].J Biol Chem, 1992, 267 (13) :8834-8839.

[34]BOUGHTON-SMITH NK, EVANS SM, LASZLO F, et al.The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat[J].Br J Pharmacol, 1993, 110 (3) :1189-1195.

[35]FANG H, CHEN M, DING Y, et al.Imaging superoxide flash and metabolism-coupled mitochondrial permeability transition in living animals[J].Cell Res, 2011, 21 (9) :1295-1304.

[36]MA Q, FANG H, SHANG W, et al.Superoxide flashes:Early mitochondrial signals for oxidative stress-induced apoptosis[J].J Biol Chem, 2011, 286 (31) :27573-27581.

[37]YANG J, LIU X, BHALLA K, et al.Prevention of apoptosis by Bcl-2:release of cytochrome c from mitochondria blocked[J].Science, 1997, 275 (5303) :1129-1132.

[38]CHEN Q, CHAI YC, MAZUMDER S, et al.The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction[J].Cell Death Differ, 2003, 10 (3) :323-334.

[39]CHORNA SV, DOSENKO VIE, STRUTYNS'KA NA, et al.Increased expression of voltage-dependent anion channel and adenine nucleotide translocase and the sensitivity of calcium-induced mitochondrial permeability transition opening pore in the old rat heart[J].Fiziol Zh, 2010, 56 (4) :19-25.

[40]SCHRIEWER JM, PEEK CB, BASS J, et al.ROS-mediated PARP activity undermines mitochondrial function after permeability transition pore opening during myocardial ischemia-reperfusion[J].J Am Heart Assoc, 2013, 2 (2) :e000159.

[41]GE ZC, XU HY, HOU WS, et al.Analysis of clinical characteristics and related factors affecting the prognosis of varies liver failure[J].J Clin Hepatol, 2009, 25 (5) :352-354. (in Chinese) 葛宗成, 许慧阳, 候为顺, 等.不同类型肝衰竭临床特点及其转归相关危险因素分析[J].临床肝胆病杂志, 2009, 25 (5) :352-354.

[42]DUAN ZP, CHEN Y.Recent progress and future perspectives of liver failure diagnosis and treatment strategies[J].J Clin Hepatol, 2012, 28 (10) :721-725. (in Chinese) 段钟平, 陈煜.肝衰竭诊疗:进展与展望[J].临床肝胆病杂志, 2012, 28 (10) :721-725.

[43]CHAPPELL JB, CROFTS AR.Calciumion accumulation and volume changes of isolated liver mitochondria.Calciumion-induced swelling.[J].Biochem J, 1965, 95:378-386.

[44]SEN S, DAVIES NA, MOOKERJEE RP, et al.Path physiological effects of albumin dialysis in acute-on-chronic liver failure:a randomized controlled study[J].Liver Transpl, 2004, 10 (9) :1109-1119.

[45]HIGUCHI M, AGGARWAL BB, YEH ET.Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function[J].J Clin Invest, 1997, 99 (7) :1751-1758.

[46]SCHULZE-OSTHOFF K, BAKKER AC, VANHAESEBROECK B, et al.Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions[J].J Biol Chem, 1992, 267 (8) :5317-5323.

[47]VALLANCE P, MONCADA S.Hyperdynamic circulation in cirrhosis:a role for nitric oxide?[J].Lancet, 1991, 337 (8744) :776-778.

[48]HELMY A, JALAN R, NEWBY DE, et al.Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis[J].Hepatology, 2001, 33 (4) :826-831.

Relative Articles

[1]	Huimin LI, Yizhuo CHEN, Rui ZHAO, Xiao HUANG, Fei HUANG, Huanhuan LI. A comparative analysis of the hemogram and myelogram of patients with liver cirrhosis and the advantages and disadvantages of splenectomy[J]. Journal of Clinical Hepatology, 2023, 39(9): 2217-2224. doi: 10.3969/j.issn.1001-5256.2023.09.028
[2]	Yitong BAI, Lianjie LIN, Dongmei PEI. Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(4): 805-809. doi: 10.3969/j.issn.1001-5256.2022.04.013
[3]	Mou SiYu, Yang Zhe, Wu LiQun, Qiu Xuan, Guo JiaMing. Predictive factors for portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 106-111. doi: 10.3969/j.issn.1001-5256.2018.01.022
[4]	Ao Fei, Chen WeiQing. Research advances in portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(3): 631-634. doi: 10.3969/j.issn.1001-5256.2018.03.043
[5]	Bao WenChun, Qi XingShun, Tang ShanHong, Li HongYu. An excerpt of the Japanese research group on IPH: diagnosis and treatment guidelines for aberrant portal hemodynamics (2017)[J]. Journal of Clinical Hepatology, 2017, 33(3): 432-434. doi: 10.3969/j.issn.1001-5256.2017.03.006
[6]	Liu ShuYan. Association between cerebral hemodynamic changes and neonatal hyperbilirubinemia[J]. Journal of Clinical Hepatology, 2017, 33(10): 1974-1976. doi: 10.3969/j.issn.1001-5256.2017.10.025
[7]	Tang HanQiu. Clinical effect of laparoscopic splenectomy combined with esophagogastric devascularization in treatment of liver cirrhosis with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(9): 1743-1746. doi: 10.3969/j.issn.1001-5256.2016.09.022
[8]	Liang XiaoHua, Zhang Feng, Zhu GeYuZheng. Effect of transjugular intrahepatic portosystemic shunt combined with splenic artery embolization on hepatic hemodynamics and liver function in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2112-2117. doi: 10.3969/j.issn.1001-5256.2016.11.021
[9]	Bao HanKang, Wei XiuLi. Clinical effects of hand-assisted laparoscopic vs open splenectomy combined with pericardial devascularization the treatment of portal hypertension in liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 431-433. doi: 10.3969/j.issn.1001-5256.2015.03.027
[10]	Yang ZhengMao, Zhang LingYi. Risk factors for portal vein thrombosis following splenectomy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(7): 1173-1175. doi: 10.3969/j.issn.1001-5256.2015.07.044
[11]	Duan LiWei, Sun Han, Chen YongSheng, Tian YueLi, Li DongFu. Hemodynamic effects of partial splenic artery embolization in patients with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2013, 29(2): 142-145.
[12]	Shang JianZhong, Ma LongFei, Ma HongWei, Zhao QiuFang, Zhao LinHua, Li XiaoFei, Fan YanFeng, Zhang SuE. Effect of autologous bone marrow- derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 848-851. doi: 10.3969/j.issn.1001-5256.2013.10.012
[14]	Jin HongHui, Ding XiaoHong. ROC curve analysis of blood platelet and hyaluronic acid levels for diagnosing cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(6): 456-458.
[15]	Gao Lei, Jing Xiang, Zhao XinMin, Zuo YanLing. Hemodynamics of portal vein in cirrhotic patients with esophageal varices[J]. Journal of Clinical Hepatology, 2010, 26(3): 297-299+305.
[16]	Liu SuLi, Feng ZhiJie, Lu: YanChun, Niu FaLiang. The clinical study of Rhizoma alismatis on hemodynamics of liver cirrohosis and portal hypertension[J]. Journal of Clinical Hepatology, 2006, 22(2): 119-120.
[17]	Qin YouJuan. Correlative study between hemodynamics of portal vein system and Child-Pugh in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 21-22.
[18]	Wang ZhiHua, Cai HanZhi, Zhao AnXin, Li XiLing, Yang HongXin. The effects of disconnection and shunt procedure on hepatic hemodynamics and function of active cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2002, 18(5): 309-310.
[19]	Dong JiLiang, Sun Jie, Ding XiuHe. Clinical observation of the effects of partial splenic embobization (PSE) on hemodynamics in 24 patients of liver cirrhosis with portal hypertention (LCPH)[J]. Journal of Clinical Hepatology, 2002, 18(6): 361-362.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	康志龙，周益民，宋燕州，张昆，苏一男，魏文平，赵新，李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 .
2.	许海明，胡永奎，梁平，钟腾猛，陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 .
3.	彭林辉，陈涛，徐云修修，王捷，陈捷，李永，黄拼搏，钟国平，陈茜，叶聪婷，陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 .
4.	李洁，李瑞娟，鲁志兵，曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 .
5.	黄乾鑫，神斌，肖晋昌，高志康，吕墩涛，李艳，徐浩，张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2778) PDF downloads(618)

Research advances in oxidative stress and mitochondrial permeability transition in liver failure

DOI: 10.3969/j.issn.1001-5256.2013.09.021